Positive News SentimentPositive NewsNYSE:AORT Artivion (AORT) Stock Price, News & Analysis $28.27 +0.24 (+0.86%) (As of 11/22/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends About Artivion Stock (NYSE:AORT) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Artivion alerts:Sign Up Key Stats Today's Range$28.03▼$28.7950-Day Range$24.97▼$29.4152-Week Range$16.48▼$30.00Volume222,367 shsAverage Volume231,457 shsMarket Capitalization$1.19 billionP/E RatioN/ADividend YieldN/APrice Target$31.00Consensus RatingBuy Company OverviewArtivion, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo. It offers E-xtra design engineering systems for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, a stent graft system for the treatment of infrarenal abdominal aortic aneurysms. In addition, the company offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; cardiac laser therapy products for angina treatment; CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; On-X prosthetic aortic and mitral heart valves and the On-X ascending aortic prosthesis; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as pyrolytic carbon coating services to medical device manufacturers. It serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. The company was formerly known as CryoLife, Inc. and changed its name to Artivion, Inc. in January 2022. Artivion, Inc. was incorporated in 1984 and is headquartered in Kennesaw, Georgia.Read More… Ever heard of this 8-day bitcoin profit window? (Ad)Did you know Bitcoin almost always soars higher during an 8-Day Profit Window? Most people have no clue… But for over a year now, some of our top students have had the chance to cash in with some incredible gains during this 8-day window.It’s coming up quick. Artivion Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks24th Percentile Overall ScoreAORT MarketRank™: Artivion scored higher than 24% of companies evaluated by MarketBeat, and ranked 848th out of 956 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.5 / 5Analyst RatingBuy Consensus RatingArtivion has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 5 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageArtivion has only been the subject of 4 research reports in the past 90 days.Read more about Artivion's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth52.17% Earnings GrowthEarnings for Artivion are expected to grow by 52.17% in the coming year, from $0.23 to $0.35 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Artivion is -1,413.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Artivion is -1,413.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioArtivion has a P/B Ratio of 3.89. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Artivion's valuation and earnings. Short Interest0.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.62% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently increased by 0.33%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldArtivion does not currently pay a dividend.Dividend GrowthArtivion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted7.62% of the float of Artivion has been sold short.Short Interest Ratio / Days to CoverArtivion has a short interest ratio ("days to cover") of 13.7, which indicates bearish sentiment.Change versus previous monthShort interest in Artivion has recently increased by 0.33%, indicating that investor sentiment is decreasing. News and Social Media2.6 / 5News SentimentN/A News SentimentArtivion has a news sentiment score of 1.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.49 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Artivion this week, compared to 2 articles on an average week.Search InterestOnly 1 people have searched for AORT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Artivion to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Artivion insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $409,501.00 in company stock.Percentage Held by InsidersOnly 8.10% of the stock of Artivion is held by insiders.Percentage Held by Institutions86.37% of the stock of Artivion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Artivion's insider trading history. Receive AORT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Artivion and its competitors with MarketBeat's FREE daily newsletter. Email Address AORT Stock News HeadlinesArtivion, Inc. (AORT) Q3 2024 Earnings Call TranscriptNovember 9, 2024 | seekingalpha.comArtivion Inc (AORT) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic AdvancesNovember 9, 2024 | finance.yahoo.comBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.November 24, 2024 | Genesis Gold Group (Ad)Artivion price target raised to $32 from $29.60 at LadenburgNovember 9, 2024 | markets.businessinsider.comArtivion (AORT) Gets a Buy from OppenheimerNovember 9, 2024 | markets.businessinsider.comWhere Artivion Stands With AnalystsNovember 8, 2024 | benzinga.comArtivion’s Q3 2024: Revenue Growth and Strategic ProgressNovember 8, 2024 | markets.businessinsider.comArtivion’s Strong Financial Performance and Strategic Growth Opportunities Drive Buy RatingNovember 8, 2024 | markets.businessinsider.comSee More Headlines AORT Stock Analysis - Frequently Asked Questions How have AORT shares performed this year? Artivion's stock was trading at $17.88 at the beginning of the year. Since then, AORT shares have increased by 58.1% and is now trading at $28.27. View the best growth stocks for 2024 here. How were Artivion's earnings last quarter? Artivion, Inc. (NYSE:AORT) announced its earnings results on Thursday, February, 17th. The company reported ($0.51) EPS for the quarter, missing the consensus estimate of ($0.06) by $0.45. The company earned $79.39 million during the quarter, compared to analyst estimates of $78 million. Artivion had a positive trailing twelve-month return on equity of 5.15% and a negative net margin of 0.22%. Who are Artivion's major shareholders? Top institutional shareholders of Artivion include Wellington Management Group LLP (3.95%), State Street Corp (3.61%), Geode Capital Management LLC (2.10%) and Royce & Associates LP (2.08%). Insiders that own company stock include James P Mackin, David Ashley Lee, Jean F Holloway, Marshall S Stanton, Andrew M Green, Rochelle L Maney, Dennis B Maier and Matthew A Getz. View institutional ownership trends. How do I buy shares of Artivion? Shares of AORT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Artivion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Artivion investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), TotalEnergies (TTE) and Southern First Bancshares (SFST). Company Calendar Last Earnings2/17/2022Today11/24/2024Fiscal Year End12/31/2024Next Earnings (Estimated)2/20/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:AORT CUSIPN/A CIK784199 Webwww.cryolife.com Phone(770) 419-3355Fax770-426-0031Employees1,500Year FoundedN/APrice Target and Rating Average Stock Price Target$31.00 High Stock Price Target$33.00 Low Stock Price Target$30.00 Potential Upside/Downside+9.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)($0.02) Trailing P/E RatioN/A Forward P/E Ratio122.91 P/E GrowthN/ANet Income$-30,690,000.00 Net Margins-0.22% Pretax Margin2.21% Return on Equity5.15% Return on Assets1.91% Debt Debt-to-Equity Ratio0.71 Current Ratio1.88 Quick Ratio1.33 Sales & Book Value Annual Sales$354 million Price / Sales3.35 Cash Flow$0.77 per share Price / Cash Flow36.48 Book Value$7.27 per share Price / Book3.89Miscellaneous Outstanding Shares41,920,000Free Float38,524,000Market Cap$1.19 billion OptionableOptionable Beta1.75 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NYSE:AORT) was last updated on 11/24/2024 by MarketBeat.com Staff From Our PartnersNew post-election stock warning from Wall StreetIf you’re holding U.S. stocks, it may be time to brace for impact. The S&P 500 crossed 6,000 for the first ...Chaikin Analytics | SponsoredPopular Stocks at Risk Under Trump—Are You Holding These?The Stocks Most At-Risk from Trump’s Victory Free e-book reveals sectors – and stocks within them – likely ...StockEarnings | SponsoredDonald Trump can’t save you from this crisisElon Musk: “This Is The Most Destructive Force In History” Elon Musk claims a terrifying new economic force...Wide Moat Research | Sponsored📉 Warning: Market Crash Predicted - Secure Your SavingsThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredShocking footage from Bill Gates’ $100,000,000,000 AI BetIf you missed out on Nvidia, watch this video I just made.Brownstone Research | Sponsored[Urgent] Starlink Set For The Largest IPO In History?He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it a...Paradigm Press | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Artivion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Artivion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.